Association of Cholinergic Muscarinic M4 Receptor Gene Polymorphism with Schizophrenia

Autor: Pozhidaev IV, Boiko AS, Loonen AJM, Paderina DZ, Fedorenko OY, Tenin G, Kornetova EG, Semke AV, Bokhan NA, Wilffert B, Ivanova SA

Publikováno v: The Application of Clinical Genetics, Vol Volume 13, Pp 97-105 (2020)

Ivan V Pozhidaev,1,2 Anastasiia S Boiko,1 Anton JM Loonen,3 Diana Z Paderina,1,2 Olga Yu Fedorenko,1,4 Gennadiy Tenin,5 Elena G Kornetova,1,6 Arkadiy V Semke,1 Nikolay A Bokhan,1,2,6 Bob Wilffert,3,7 Svetlana A Ivanova1,4,6 1Mental Health Research In

Externí odkaz: https://doaj.org/article/39429ef3f13f4e2dae2a6dd1fd1cd15a

The functional variant rs334558 of GSK3B is associated with remission in patients with depressive disorders

Autor: Levchenko A, Losenkov IS, Vyalova NM, Simutkin GG, Bokhan NA, Wilffert B, Loonen AJM, Ivanova SA

Publikováno v: Pharmacogenomics and Personalized Medicine, Vol Volume 11, Pp 121-126 (2018)

Anastasia Levchenko,1,* Innokentiy S Losenkov,2,* Natalia M Vyalova,2 German G Simutkin,2 Nikolay A Bokhan,2,3 Bob Wilffert,4,5 Anton JM Loonen,4,6 Svetlana A Ivanova2,7 1Institute of Translational Biomedicine, Saint Petersburg State University, Sain

Externí odkaz: https://doaj.org/article/f4051f5db5cc4d57b13681d19a122504

Pharmacogenetic Information in Clinical Guidelines: The European Perspective

Autor: Swen, J.J., Nijenhuis, M., Rhenen, M. van, Boer-Veger, N.J. de, Buunk, A.M., Houwink, E.J.F., Mulder, H., Rongen, G.A., Schaik, R.H.N. van, Weide, J. van der, Wilffert, B., Deneer, V.H.M., Guchelaar, H.J., Royal Dutch Pharmacists Assoc KNMP

Publikováno v: Clinical Pharmacology and Therapeutics, 103(5), 795-801
Clinical Pharmacology and Therapeutics, 103, 5, pp. 795-801
Clinical Pharmacology and Therapeutics, 103, 795-801
Clinical Pharmacology & Therapeutics, 103(5), 795-801. Wiley-Blackwell

Item does not contain fulltext Surveys among pharmacists and physicians show that these healthcare professionals have successfully adopted the concept of pharmacogenomics (PGx).(1-3) In addition, patients are willing to consent to participate in PGx

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9f278e481229e5b1cd2028f6a148372
https://doi.org/10.1002/cpt.1049

The association between the NAT2 genetic polymorphisms and risk of DILI during anti-TB treatment: a systematic review and meta-analysis

Autor: Zhang, M, Wang, S, Wilffert, B., Tong, R., Soolingen, D. van, Hof, S. van den, Alffenaar, J.W.C.

Publikováno v: British Journal of Clinical Pharmacology, 84, 12, pp. 2747-2760
British Journal of Clinical Pharmacology, 84, 2747-2760

Contains fulltext : 200451.pdf (Publisher’s version ) (Open Access) AIMS: The aim of this study is to evaluate the potential association between N-acetyltransferase type 2 (NAT2) polymorphisms and drug-induced liver injury during anti-TB treatment

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::09697ddbf9d50010701abefbdd8420e3
https://hdl.handle.net/2066/200451

P.583 Polymorphisms in BDNF, AKT1, GSK3B genes: possible association with antipsychotic-induced hyperprolactinemia in schizophrenia patients

Autor: Ivanova, S.A., Paderina, D.Z., Boiko, A.S., Pozhidaev, I.V., Kornetova, E.G., Wilffert, B., Loonen, A.J.M.

Publikováno v: In European Neuropsychopharmacology November 2020 40 Supplement 1:S331-S332